Stocktoria
Monte Rosa Therapeutics, Inc. GLUE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-24
Chart by TradingView
5/9
Piotroski F — financial health
1.67
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $123.7M | $75.6M | $0 | — | — |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M | -$72.9M |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M | -$74.0M |
| Operating cash flow | -$22.8M | $42.0M | -$43.8M | -$92.5M | -$59.4M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M | -$69.1M |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M | $366.3M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M | $18.8M |
| Shareholders' equity | $233.1M | $222.9M | $179.2M | $271.4M | $347.5M |
| Ratios | |||||
| Operating margin | -43.8% | -107.3% | — | — | — |
| Net margin | -31.2% | -96.1% | — | — | — |
| FCF margin | -22.2% | 50.3% | — | — | — |
| Return on assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% |
| Return on equity | -16.6% | -32.6% | -75.5% | -40.0% | -21.3% |
| Current ratio | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 |
| Revenue growth | 63.5% | — | — | — | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 379,100 | $6.2M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.67 (grey)
- Working capital / assets 0.733
- Retained earnings / assets -1.064
- EBIT / assets -0.121
- Equity / liabilities 1.081
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001826457 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.